ArticleAging clinical and experimental research2026
An exploratory multi-biomarker panel including fecal calprotectin, Brain-Derived Neurotrophic Factor, Fibroblast-Growth Factor-21 and irisin shows poor diagnostic accuracy for detecting probable sarcopenia in community-dwelling older persons.
Article in Aging clinical and experimental research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biomarkers and Early Mechanisms of Sarcopenia: Central Roles of Mitochondrial Dysfunction, Inflammaging, Cellular Senescence, and Neuromuscular Degeneration.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundsSerum and fecal biological markers that reflect underlying drivers of sarcopenia, may aid in novel predictive or diagnostic tools for sarcopenia.
aimsTo explore the potential of five specific myokines and fecal calprotectin (fCPT) as biomarkers for diagnosing the presence of at least probable sarcopenia in community-dwelling individuals aged ≥ 65 years.
methodsThis cross-sectional, exploratory study included 156 participants (median age 73y), of whom 59 (20♂, 39♀) had at least probable sarcopenia per EWGSOP2 criteria, and 97 (33♂, 64♀) controls. Myostatin, irisin, Brain-Derived Neurotrophic Factor (BDNF), Insulin-like Growth Factor-1 (IGF-1), Fibroblast Growth Factor-21 (FGF-21), and fCPT were measured using Enzyme-Linked ImmunoSorbent Assay (ELISA). Muscle mass and function were assessed via appendicular lean mass (ALM), hand grip strength (HGS), 5-time chair stand test (CST), gait speed, and the Short Physical Performance Battery (SPPB). Linear and logistic regressions analyses were performed. Diagnostic accuracy was evaluated using Area’s Under the Curve (AUC).
resultsParticipants with fCPT < 50 µg/g walked faster than those with fCPT ≥ 200 µg/g. Higher fCPT associated with slower gait speed (β: -0.003; 95% CI [-0.001; -0.00002]), while IGF-1 associated with higher HGS (β: 0.077; 95% CI [0.039; 0.116]). BDNF alone diagnosed at least having probable sarcopenia (AUC: 0.63; sensitivity 53%, specificity 71%). A multi-biomarker panel comprising BDNF, irisin, FGF-21 and fCPT modestly improved accuracy (AUC: 0.71; sensitivity 64%, specificity 77%), but this improvement was not statistically significant compared with the single biomarkers BDNF (p = 0.330) and fCPT (p = 0.180). DISCUSSION: The multi-biomarker panel significantly diagnosed at least having probable sarcopenia, but with high false negative (36%) and positive (23%) rates, respectively.
conclusionThe clinical relevance of this specific multi-biomarker panel may be limited due to moderate diagnostic accuracy. Validation in larger cohorts is needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.